Geron's drug RYTELO gets European nod for treating anemia in certain blood disorder patients.

Geron Corporation's drug RYTELO has received a positive recommendation from the European Medicines Agency for treating certain types of anemia in patients with lower-risk myelodysplastic syndromes. If approved by the European Commission, RYTELO would be the first telomerase inhibitor available in Europe for this condition. The drug aims to reduce the need for blood transfusions, addressing a significant unmet need for these patients.

3 months ago
8 Articles